Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Debt to Equity (2020 - 2025)

Insight Molecular Diagnostics' Debt to Equity history spans 6 years, with the latest figure at -$0.11 for Q3 2025.

  • For Q3 2025, Debt to Equity fell 281.62% year-over-year to -$0.11; the TTM value through Sep 2025 reached -$0.11, down 281.62%, while the annual FY2024 figure was -$0.02, 116.43% down from the prior year.
  • Debt to Equity for Q3 2025 was -$0.11 at Insight Molecular Diagnostics, down from $0.63 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.63 in Q2 2025 and bottomed at -$0.11 in Q3 2025.
  • The 5-year median for Debt to Equity is $0.02 (2022), against an average of $0.05.
  • The largest annual shift saw Debt to Equity surged 3456.76% in 2023 before it crashed 281.62% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.02 in 2021, then crashed by 84.21% to $0.0 in 2022, then soared by 3456.76% to $0.11 in 2023, then plummeted by 116.43% to -$0.02 in 2024, then plummeted by 518.18% to -$0.11 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Debt to Equity are -$0.11 (Q3 2025), $0.63 (Q2 2025), and $0.04 (Q1 2025).